Novartis AG (NYSE:NVS) just announced that it will present new research that may transform the way serious blood diseases and a certain type of breast cancer are treated at the upcoming 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, December 1-4 and the 41st Annual San Antonio Breast Cancer Symposium (SABCS), December 4-8. Nearly 150 abstracts will be presented across both congresses, underscoring the strength of the Novartis pipeline and portfolio in hematology and oncology.
The release notes that attendees can expect additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer.
Novartis AG (NYSE:NVS) trumpets itself as company that researches, develops, manufactures, and markets a range of healthcare products worldwide.
The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services.
The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.
Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
As noted above, NVS just announced that it will present new research that may transform the way serious blood diseases and a certain type of breast cancer are treated at the upcoming 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, December 1-4 and the 41st Annual San Antonio Breast Cancer Symposium (SABCS), December 4-8. Nearly 150 abstracts will be presented across both congresses, underscoring the strength of the Novartis pipeline and portfolio in hematology and oncology.
The stock is up on the news. Overall, shares of NVS have rallied about 4% over the past week. That sets up an interesting context for the action tomorrow.
“Novartis Oncology has a purpose-driven legacy built on an unwavering commitment to help patients live better and longer lives,” said Liz Barrett, CEO, Novartis Oncology. “The breadth and depth of our data at these scientific forums demonstrates how we are acting on our vision to reimagine cancer in a meaningful way for patients by relentlessly pursuing scientific advancements and exploring novel combination treatment options to help those living with hard-to-treat diseases.”
Novartis AG (NYSE:NVS) pulled in sales of $12.6B in its last reported quarterly financials, representing top line growth of 5.2%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($14.4B against $27.7B, respectively).